Company Overview
AMYLYX PHARMACEUTICALS, INC.
AMLXRevenue vs. Cost of Revenue
Revenue
Cost of Revenue
Total Operating Expenses vs. Operating Income
Total Operating Expenses
Operating Income
Net Income
Net Income
Revenue
0M
2025 FY
Net Income
-145M
2025 FY
Shares Outstanding
95M
2025 FY
EPS
-1.53USD
2025 FY
Company Information
SIC Code
2834
CIK Code
1658551
Exchange
Nasdaq
Location
US